Hong Kong widens GSK antibiotic recall again

GlaxoSmithKline ($GSK) turned up plasticizers in two more strengths of its Augmentin antibiotic, triggering another recall in Hong Kong. After recalls of two other versions of the antibiotic, the company launched an internal probe, finding the chemicals in 625-mg and 1-g tablets made at a U.K. plant.

In a statement, GSK reiterated that it doesn't intentionally use the plasticizers--including diisodecyl phthalate (DIDP) and diisononyl phthalate (DINP)--in the manufacturing process. However, it has identified a potential source of the contamination.

"According to GSK's in-house search, the source of the plasticisers was possibly from abrasion of the polyvinyl chloride (PVC) plastic tubing used to transfer powder and granules during tablet production. In view of this reported quality defect, DH orders extension of the recall to cover all Augmentin tablet formulations manufactured in U.K.," according to Hong Kong's Department of Health.

The amount of plasticizers found in the tablets isn't likely to compromise safety as long as consumers take the recommended dosage, health officials said. The department hasn't received any adverse event reports related to the drug. But it's still reserving the right to take legal action against GSK if the Department of Justice finds it warranted.

- read the Health Department release
- get more from GSK
- check out the Macau Daily Times article

Related Articles
Hong Kong forces second drug recall
Hong Kong yanks GSK drug on phthalate levels

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.